Hematide

Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc. (Nasdaq:AFFY) today announced that additional Phase 2 clinical trial results for Hematide(TM) were presented at the European Renal Association-EDTA Congress being held in Barcelona, Spain by Iain C. Macdougall, M.D., a Hematide invest...

Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia

...rt Takeda's efforts in the clinical development of hematide in chemotherapy induced anemia. We are pleased wit...etics and preliminary efficacy of various doses of hematide in the correction of anemia. Initial dosing in thi...al later stage clinical trials. About Hematide hematide is a novel synthetic, pegylated peptidic compound ...

Affymax Announces Results From Phase 2 Clinical Trial of Hematide for the Treatment of Anemia in Dialysis Patients

...s safety, pharmacodynamics and pharmacokinetics of hematide in hemodialysis patients with stable baseline Hgb ...y. The endpoints were Hgb and reticulocyte levels, hematide dose adjustments and red blood cell transfusions. ...n reticulocyte increases were observed after every hematide injection. The mean Hgb level, which was 11.5 g/dL...

Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease

...wed that in treatment naive, non-dialysis patients hematide could correct anemia when administered monthly at ...evels following a switch to once monthly dosing of hematide at an appropriate dose. The data were presented by...ing held in Rio de Janeiro. "These data show that hematide results in appropriate management of hemoglobin le...

Hematide in Biological Technology

Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress

...uddock (650) 631-4954 or jruddock@nektar.com References (1) MacDougall I. et al, Interim evaluation of long-term safety and tolerability of hematide during maintenance treatment of anaemia in patients with chronic kidney disease, presented on 12 May 2008 at the 45th ERA-EDTA congress, Sto...

Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia

...izes our strategic alliance with Takeda to develop hematide worldwide as a potential treatment for anemia asso...x and Takeda have made significant progress in the hematide clinical development program. We recently initiate...tegy. We look forward to continued progress in the hematide clinical development program." Affymax and Takeda...